Systemic therapy for triple-negative breast cancer: A changing landscape

Crit Rev Oncol Hematol. 2022 Mar:171:103608. doi: 10.1016/j.critrevonc.2022.103608. Epub 2022 Jan 31.

Authors

Alaina J Kessler¹, Joseph A Sparano²

Affiliations

¹ Department of Medicine, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, United States. Electronic address: alaina.kessler@mountsinai.org.
² Department of Medicine, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, United States.

PMID: 35093499
DOI: 10.1016/j.critrevonc.2022.103608

No abstract available

Publication types

Review

MeSH terms

Humans
Triple Negative Breast Neoplasms* / drug therapy